Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Destiny Pharma Plc LSE:DEST London Ordinary Share GB00BDHSP575 ORD GBP0.01
  Price Change % Change Share Price Shares Traded Last Trade
  2.50 1.89% 134.50 78,509 12:52:53
Bid Price Offer Price High Price Low Price Open Price
132.00 137.00 135.50 132.00 132.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -6.48 -12.00 81
Last Trade Time Trade Type Trade Size Trade Price Currency
15:45:09 O 35,000 140.00 GBX

Destiny Pharma (DEST) Latest News

More Destiny Pharma News
Destiny Pharma Investors    Destiny Pharma Takeover Rumours

Destiny Pharma (DEST) Discussions and Chat

Destiny Pharma Forums and Chat

Date Time Title Posts
10/6/202117:07Destiny Pharma plc567

Add a New Thread

Destiny Pharma (DEST) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-06-11 16:15:01140.0035,00049,000.00O
2021-06-11 14:45:10133.952,1562,887.96O
2021-06-11 14:41:25134.068,69911,662.14O
2021-06-11 13:54:08134.00461617.74O
2021-06-11 13:44:11134.001,4921,999.28O
View all Destiny Pharma trades in real-time

Destiny Pharma (DEST) Top Chat Posts

DateSubject
12/6/2021
09:20
Destiny Pharma Daily Update: Destiny Pharma Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker DEST. The last closing price for Destiny Pharma was 132p.
Destiny Pharma Plc has a 4 week average price of 128.50p and a 12 week average price of 128.50p.
The 1 year high share price is 246p while the 1 year low share price is currently 30p.
There are currently 59,861,921 shares in issue and the average daily traded volume is 248,895 shares. The market capitalisation of Destiny Pharma Plc is £80,514,283.75.
10/6/2021
17:07
garth: 10 June 2021 Destiny Pharma plc ("Destiny Pharma" or the "Company") Director Dealing Destiny Pharma plc (AIM: DEST) a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, announces that it was notified on 10 June 2021 that on that same day, Dr William Love, Chief Scientific Officer of the Company, sold 350,000 ordinary shares of 1 pence in the Company ("Ordinary Shares") at a price of 120 pence. Following the sale, Dr William Love's beneficial interest in the Company is 6,509,500 Ordinary Shares, representing 10.87 per cent. of the total issued share capital. Dr Love confirms that he does not intend to sell any further Ordinary Shares for the foreseeable future, that is until 2023 at the earliest.
06/6/2021
20:33
sev22: Just to let all PIs know that a recording of the presentation: DESTINY PHARMA PLC - Annual General Meeting, along with responses to questions that were answered by the company are now available for review in the meeting archive at: https://www.investormeetcompany.com/login Just login for free to view the recording and Q&A. The presentation reinforces what a great investment case this company has. The share price has drifted down since the excellent XF-73 results. However now there are two world class phase 3 trials in preparation for XF-73 and M3. Big pharma partner discussions are ongoing to get these trials funded and started. I think DEST will have a lot of interest for both of these trials and likely be spoilt for choice with interested partners. They are in a great negotiating position and the market will eventually wake up to this as there are not many companies with such quality assets and on such a low valuation. The upside potential is massive.
26/4/2021
21:30
sev22: Thanks for your post GB904150. I re-visited the Broker note tonight, issued on the 14th April 2021 when the share price was 173p. XF-73 Phase 2b trial. Following the recent announcement of a highly statistically significant and clinically meaningful reduction of S. aureus in patients undergoing open chest open heart surgery, the company is due to meet with the FDA in Q2 2021 to discuss these results and the Phase 3 trial design. NTCD-M3 in prevention of recurrent C. difficile infection (CDI): positive Phase 2 data, with a single Phase 3 registration study having already been agreed with FDA. Unlike Faecal Matter Transplant (FMT) and their derivatives, which are likely to be limited for use by the FDA, M3 will be positioned as first-line therapy. Outlook. The company has two high-quality Phase 3-ready clinical assets targeted at infection prevention, supported by strong Phase 2 clinical data and clear commercial positioning as well as a promising pipeline of earlier-stage assets supported by grant funding and the NIH in the US. Focus for FY 2021 is to complete preparations for the trials (including CMC) to enable the start of Phase 3 trials for both assets in 2022. Forecasts and valuation. We leave our forecasts for 2021 unchanged, with year- end cash of c.£3.5m and a runway that extends to Q4 2022. We reiterate a 370p target price, underpinned by an rNPV of 372p and peer group valuations in the US that currently trade at c.£600m+. Our valuation excludes any value attributable to other drugs from the XF platform or SPOR-COV collaboration, suggesting multiple levers for further value appreciation.
26/4/2021
21:02
gb904150: hi 74tom, Thanks for alerting me to that extra info in the latest IMC presentation. I watched the presentation as I was a bit concerned at your suggestion. Neil Clark's explanation during the questions (from 26:30 if you want to skip to it) completely covered it I thought? In short, yes, the patent for NI-CD M3 expires in the next few years but they are not relying on that to give them IP protection. Instead, as it is a biological therapeutic approach they will do a biological licence application (BLA) which will give 12 years commercial protection on approval. In addition, the difficulty to manufacture gives a 2nd level of protection. NC mentions it difficult to find manufactures who can cultivate sufficient quality and consistency of live bacterial spores for the treatment. There's also a very good explanation as to why NT-CD M3 got to where it did. It was developed by Prof. Dale Gerding. He sold his invention to Immupharma. Immupharma spent approx $30m on it getting it through phase 1,2. Immupharma then got bought out by Shire. Shire's focus is solely on orphan drugs so they handed back the tech to Prof. Dale Gerding. He then solicited offers for it and as part of a competitive process DEST won the rights to develop it. As you say, it only cost £2.4m to pick up a treatment that is ready for phase 3 trials. I can imagine Prof Gerding wanted the best price but also the best chance of his life work finally making it to market! It sounds like DEST was a good fit to achieve that. It doesn't sound like there's anything more sinister than that and I trust the DEST team to have done what looks like a good deal. As I say - approx $30m spent on it already and C-diff is as big a problem as it ever was. On your point of funding options, DEST has a cash runway to late 2022 but yes, of course phase 3's will need to be funded. Options there include: equity funding, partners funding, grant funding. Grant funding in particular is a great option because there are specific AMR funds looking to invest to solve what is one of the greatest problems facing medicine. hTTps://www.gov.uk/government/groups/the-global-amr-innovation-fund hTTps://amractionfund.com/ AMR will be a major talking point of the G7 summit taking place in Cornwall this summer. Wouldn't it be convenient if a UK drug/therapeutics company could be championed as part of that? DEST are in a fantastic space at an important time. They've just announced hugely successful Phase 2b trials for XF-73 and yet they now trade at pretty much the same price they were prior to announcing that successful trial! None of that factors in any value for the rest of the XF platform nor any of the sporegen project around COVID. That said - the shorter term share price performance will depend how much funding is raised as equity. To be fair, DEST made a fair offer to existing shareholders to participate last time based on their current holdings. Remember that Bill Love holds a decent % of the shares here - owners and shareholders are aligned, so they tend not to rip off PI's with hugely discounted placings. They also seem to understand the value they are sitting on and don't undersell it.
21/4/2021
09:25
sev22: Don't forget that DEST are providing a live investor presentation on the Investor Meet Company platform tomorrow at 2pm. Neil Clark and Shaun Claydon will run through the results, strategy and prospects, DEST's pipeline followed by Q&A. https://www.investegate.co.uk/destiny-pharma-plc--dest-/rns/fy-2020-investor-presentation/202104150800045087V/
14/4/2021
07:36
edmonda: The FY results update shows how Destiny has transformed its portfolio and share price in the last year. With DEST now owning two Phase 3-ready assets, Equity Dev has a fair value of £214m or 358p / share. Read their new research note here: https://www.equitydevelopment.co.uk/research/what-a-difference-a-year-makes
14/1/2021
15:41
supracat: I had the pleasure and was fortunate enough too to be introduced to Destiny back in 2005 and invested a small amount. When they IPOd I scaled back my holding to just a few thousand shares and sold out at 130p ish. But I always liked the company and where they were headed and couldn't believe when that price dropped to low 30s and therefore built my holding each day by snapping up shares in the low to high 30s over a period of months. Probably sustained the share price in the 30s at the time with these purchases as others bailed out. Who knows where the journey will end up but for me personally I like the story, I like destiny's patient approach and their gutsy motive to acquire another product at phase 3 to complement thier pipeline. Xf73 P2b trial will clearly be a key driver to ultimate value so let's see where this ride goes. I'm a believer and certainly hope another Novacyt here.
03/12/2020
11:23
neo2725: Some calculations for us all, I have been working out the free float before and after the recent placing, before is easy to work out via the destiny website under the capital structure tab or just type destiny pharma major stakeholders into google and it’s the first link. It was 66.6% of all shares held by major investors so a free float of shares for us PIs of 33.4% of remaining shares. Now after the recent placing we need to dilute these down by the additional 15.9million new shares which hit the market on Monday giving 59,816,921 shares currently in issue, about a 26% dilution by my maths, factor in the two RNS from Sir Nigel Rudd and Unicorn assets management who have taken a 3% and 5% stake this gives a current free float of about 43% shares in private hands. This is 25,700,000 shares give or take, I imagine as we approach results in q1 2021 this pool of shares will reduce and we may see increase in share price. I cannot see people who have taken part in the placing selling for sub 65p. With broker targets of £2.60 and £3 on a successful trial this share has much upside and little down IMO but do your own research.
27/7/2020
09:54
hedgehog 100: 27/07/2020 07:00 UKREG Destiny Pharma PLC Update on Phase 2b clinical study of XF-73 Update on Phase 2b clinical study of lead asset XF-73 in the prevention of post-surgical bacterial infections Protocol amendment agreed with FDA to reduce Phase 2b study size without compromising its statistical power or clinical value Study two thirds enrolled. Recruitment now expected to complete by year end Planned study interim safety review to be announced in August 2020 Brighton, United Kingdom - 27 July 2020 - Destiny Pharma plc (AIM: DEST), a clinical stage biotechnology company focused on the development of novel treatments for hospital infections that address the global challenge of antimicrobial resistance (AMR), is pleased to announce a clinical protocol amendment has been agreed with FDA for its ongoing phase 2b study of lead asset XF-73. The study is evaluating XF-73, as a nasal gel, for the prevention of post-surgical hospital infections caused by Staphylococcus aureus bacteria, such as MRSA. The agreed amendment recognizes the impact COVID-19 has had in slowing patient recruitment in clinical studies since March and the FDA's willingness to support certain protocol amendments that help to accelerate the completion of ongoing clinical trials but do not compromise a study's integrity and clinical objectives. The amendment to the protocol incorporates a change to the primary patient population where the primary endpoint for the study will be measured. The primary microbiological endpoint post-surgery will now be measured in those patients who had a positive load of nasal Staphylococcus aureus before receiving the study treatment. This contrasts to the original primary population, which included all randomised patients regardless of their baseline nasal load of Staphylococcus aureus. Very importantly, this change enables a reduction in the prospectively defined study size from 200 patients to 125 while maintaining the statistical power of the study and its clinical value. This preserves the potential of the trial results to be a key step towards the Phase 3 clinical trial programme of XF-73. Destiny Pharma has informed all appropriate regulatory bodies and ethics committees involved. Other protocol modifications agreed with the FDA regarding study procedures will also make it easier for hospitals to recruit and retain hospital patients. Destiny Pharma expects that as the incidence of COVID-19 continues to decline in European hospitals they will begin recruiting patients into the study again and that recruitment into US study sites is likely to lag, given the higher infection incidence. That said, the study has already enrolled 77 patients out of the new target of 125 and the Company expects to have over 20 sites open in three countries actively recruiting the remaining patients in the next few months with the majority of these being FDA-compliant sites in Europe. The study remains on track to complete recruitment by the end of 2020. The result of a planned interim safety review by the study's Independent Safety Monitoring Board is expected to be announced in August 2020. Neil Clark, Chief Executive Officer of Destiny Pharma, commented: "We are very pleased to have agreed the protocol amendment with the FDA. The changes will help us complete recruitment later in 2020 and still be well placed to move towards Phase 3 clinical studies if the Phase 2b results are positive. Destiny Pharma is funded through to the last quarter of 2021 and remains confident in the clinical need and significant commercial opportunity for its lead clinical asset XF-73 as a novel preventive treatment of serious hospital infections". https://uk.advfn.com/stock-market/london/destiny-pharma-DEST/share-news/Destiny-Pharma-PLC-Update-on-Phase-2b-clinical-stu/82925846
22/7/2020
16:53
hedgehog 100: 15/07/2020 07:00 RNSNON Destiny Pharma PLC Destiny Pharma notes launch of AMR Action Fund Destiny Pharma notes launch of $1 billion pharma-backed fund to develop new anti-infectives Fund underlines the market urgency for the development of novel safe and effective antimicrobials such as Destiny Pharma's lead asset, XF-73 XF-73 is currently in a phase 2b clinical study investigating its use in the prevention of post-surgical bacterial infections Brighton, United Kingdom - 15 July 2020 - Destiny Pharma plc (AIM: DEST), a clinical stage biotechnology company focused on the development of novel, hospital infection prevention treatments that address the global challenge of antimicrobial resistance (AMR), notes the launch of the AMR Action Fund to provide financial resources and technical support to help biotechnology companies bring novel anti-infective drugs to patients. These are needed urgently to fight the worldwide rise in antimicrobial-resistant superbugs. Over 20 leading pharmaceutical companies have pledged to invest a total of $1 billion in a fund to help bridge innovative candidates in the pipeline through the later stages of drug development and to work with governments to ensure there is a sustainable pipeline of new antibiotics that address AMR. The pharmaceutical industry, in collaboration with the World Health Organization, the European Investment Bank, and the Wellcome Trust, have joined forces to design the fund, which aims to bring between two and four new antibiotics to market by 2030. For more information visit hxxps://amractionfund.com . This new pharma-backed fund underlines the urgency for the development of novel safe and effective antimicrobials such as Destiny Pharma's lead asset, XF-73. XF-73 is currently in a phase 2b clinical study investigating its use in the prevention of post-surgical bacterial infections, including the superbug MRSA. Neil Clark, Chief Executive Officer of Destiny Pharma, commented: "We welcome this significant new fund supporting novel drug development addressing AMR. The world needs new anti-infective drugs and Destiny Pharma is one of the leading biotechnology companies dedicated to addressing this global clinical need. The new pharma backed fund is the latest in a series of new initiatives from regulators, governments and healthcare investors to support innovation that addresses AMR." https://uk.advfn.com/stock-market/london/destiny-pharma-DEST/share-news/Destiny-Pharma-PLC-Destiny-Pharma-notes-launch-of/82855641
Destiny Pharma share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
DEST
Destiny Ph..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210612 12:30:26